Where results make sense

About us   |   Why use us?   |   Reviews   |   PR   |   Contact us

Alphapharm - Copyright, Disclaimer & Privacy Policy Alphapharm is a proud supporter of the Australian Made Campaign. Neither Alphapharm Pty Ltd nor any party involved in creating, producing or delivering this website shall be liable for any direct, incidental, consequential, indirect or punitive loss or damages arising out of access to, use of or inability to use this website, or any errors or omissions in the content thereof. Alphapharm is bound by the National Privacy Principles under the Privacy Act. www.alphapharm.com.au /page.php?id=2457   (961 words)

law.com - Decision According to Alphapharm, the record established that compound b was the most effective antidiabetic compound in the prior art, and thus the court erred by failing to apply a presumption that one of ordinary skill in the art would have been motivated to make the claimed compounds. Alphapharm relies on In re Wilder, 563 F.2d 457 (CCPA 1977), for the proposition that differences in a chemical compound's properties, resulting from a small change made to the molecule, are reasonably expected to vary by degree and thus are insufficient to rebut a prima facie case of obviousness. Alphapharm asserts that the court excluded the prosecution history of the '779 patent from the scope of the prior art after wrongly concluding that it was not accessible to the public. www.law.com /jsp/decisionstate.jsp?id=1184231191461   (5305 words)

Patent Docs: Takeda Chem. Indus., Ltd. v. Alphapharm Pty., Ltd. (Fed. Cir. 2007) During a bench trial on the issues of validity and enforceability, Alphapharm argued that the claimed compounds would have been obvious at the time of their invention in view of a prior art compound known as "compound b." Compound b possesses a pyridyl ring in which a methyl (CH3) group is attached to the 6-position: First, Alphapharm argued that one of ordinary skill in the art would have selected compound b as a lead compound on which to perform further chemical modifications. Second, Alphapharm argued that the skilled artisan would have made two obvious chemical changes to compound b; namely, replacing the methyl group at the 6-position of compound b with an ethyl group (homologation) and moving the ethyl group from the 6-position to other positions on the pyridyl ring (ring-walking) - including the 5-position of pioglitazone. patentdocs.typepad.com /patent_docs/2007/07/takeda-chem-ind.html   (1380 words)

Toll (FGCT) v. Alphapharm Alphapharm and Ebos commenced proceedings against Toll, claiming damages for negligence as bailee in the amount of A$683,061.86. Judgment was entered in favour of Alphapharm and Ebos in both the District Court of New South Wales and Court of Appeal of New South Wales. The evidence "compelled the conclusion" that Alphapharm had authorised Richard Thomson to contract with Toll and agree on freight rates, payment terms and such other standard terms and conditions of contract as were required by Toll. www.onlinedmc.co.uk /toll_(fgct)_v__alphapharm.htm   (1108 words)

Barry & Nilsson Brisbane Lawyers - Commercial Alert - 15 December 2004 In Toll v Alphapharm, the High Court decided a case where the person who had signed that document asserted they should not be bound by the document as they did not read it prior to signing. Alphapharm had agreed to use Finemores to store and transport the fluvirin to reduce handling, as the importer who had sold the fluvirin to Alphapharm also used Finemores. Alphapharm sued Finemores for its losses in relation to the consignments (approximately $680,000.00), and Finemores attempted to rely upon the exclusion clause in the conditions of contract. www.barrynil.com.au /content/standard_c3.asp?name=CommercialLaw_Alert5   (552 words)

The pioglitazone generic move - Features In their Para IV certifications, both Alphapharm and Mylan claimed that the 777 patent was invalid due to obviousness and forwarded notice of Para IV certification to Takeda that included detailed statements under 21 USC 21§ 355 (j) (2) (b) (ii) clarifying the legal basis of their positions. Alphapharm also contended in their notice that pioglitazone covered by 777 patent is prima facie obvious over the prior art compound, disclosed in 200 patent and published article of Dr Sohda. Alphapharm argued that the prior art clearly identified compound 58 as a lead compound warranting further investigation, and that the application of a few, obvious chemical processes would have produce pioglitazone. www.pharmabiz.com /article/detnews.asp?articleid=33543§ionid=46   (982 words)

Patent Baristas » For Chemical Obviousness, Need to Show That Prior Art Suggested Making Modifications to Get ... Alphapharm and Genpharm (06-1329), The U.S. Court of Appeals for the Federal Circuit upheld an earlier decision in the district court finding that U.S. Patent 4,687,777 was not invalid under 35 U.S.C. Takeda Chem. First, Alphapharm argued that the district court misapplied the law, particularly the law governing obviousness in the context of structurally similar chemical compounds. According to Alphapharm, compound b was the most effective antidiabetic compound in the prior art, and thus the court erred by failing to apply a presumption that one of ordinary skill in the art would have been motivated to make the claimed compounds. www.patentbaristas.com /archives/2007/07/03/for-chemical-obviousness-need-to-show-that-prior-art-suggested-making-modifications-to-get-claimed-compound   (1158 words)

PHC : ALPHAPHARM Article   (Site not responding. Last check: 2007-11-01) Alphapharm was founded in 1982, as a pharmaceutical manufacturing concern employing four staff. The interim rating for Alphapharm’s business planning and control systems as a result of this assessment was a high class D level of performance (A being the highest score and D the lowest). Alphapharm will implement a process whereby generic bulk tablets and capsules for some of our Asian export markets will be held in stock, only to be packed when firm orders are received. www.heenan.com.au /articles/alphapharm.html   (3941 words)

Law.com - Federal Judge Awards $16.8M in Pharmaceutical Patent Case Alphapharm was represented by Edgar H. Haug, Kevin Murphy and Jeffrey A. Hovden of Frommer Lawrence & Haug. Mylan and Alphapharm attempted to override Takeda's patent on pioglitazone by arguing that the patent was unenforceable because the invention was "obvious" and because Takeda engaged in "inequitable conduct" when applying for its patent. Judge Cote disagreed, however, saying in a Feb. 21, 2006, opinion that Alphapharm had failed to show by clear and convincing evidence that the "ordinary artisan would have had sufficient motivation to take each of the conceptual and experimental steps that were necessary to... www.law.com /jsp/article.jsp?id=1174554225741   (579 words)

Takeda Pharmaceutical Co. Ltd. Wins Patent Infringement Litigation Against ANDA Filers For Generic ACTOS(R) ... A federal judge of the U.S. District Court for the Southern District of New York ruled on February 21, 2006 that a patent covering the active ingredient of ACTOS is valid and enforceable. Alphapharm and Mylan were the only defendants to challenge the '777 patent. Trial of the challenges by Alphapharm and Mylan to the validity and enforceability of the '777 patent took place from January 17, 2006 to January 30, 2006. www.biospace.com /news_story.aspx?StoryID=10555   (451 words)

Alphapharm Pty Ltd Alphapharm Pty Ltd is a leader in the development, manufacture, marketing, distribution and export of Australian made generic prescription and pharmacy-only medicines. Alphapharm manufactures over 200 different products and distributes to some 40 countries around the globe. Alphapharm's Training and Development Coordinator, Maria Asmus, says everyone in the company is involved with on-going training and skills development - from the laboratory to management. www.createitmakeitliveit.qld.gov.au /dsdweb/v3/guis/templates/content/gui_cue_cntnhtml.cfm?id=17684   (341 words)

QMI Solutions Ltd - How Alphapharm 'slowed down' to speed up Alphapharm also realised that TPM alone wouldn't raise manufacturing efficiency as the laboratory teams weren't engaged by a program that they saw was about machines and the factory and not about their scientific labs. Alphapharm have already addressed the first area of concern (pull) with the quality control team by ensuring that they can support a full system going through the factory. Alphapharm will be relying on a Six Sigma system to develop improvements in their 'quality at source' issues. www.qmisolutions.com.au /article.asp?aid=219   (1943 words)

VELOCITY - Life Sciences - Case Studies   (Site not responding. Last check: 2007-11-01) Alphapharm, Australia's largest supplier of prescription medicines to the Pharmaceutical Benefits Schedule and leading manufacturer of Australian made tablets and capsules is significantly expanding its operations in Queensland. Poised for further growth, Alphapharm chose to expand in Queensland rather than Canada or Ireland due to the pool of highly qualified people in the state. Alphapharm distributes over 2.2 billion tablets and capsules to over 5,000 customers in Australia, as well as to customers in more than 30 export markets each year, all of which are manufactured in Brisbane. www.velocitybrisbane.com /industries/lifesciences/casestudies/alpha.asp   (309 words)

Diabetes Australia - NSW. The only charity dealing with all people with diabetes. More recently, Alphapharm have distributed a wide variety of diabetes patient information, as well as DA and NDSS enrolment forms, to ensure patients’ get the best support early in disease management. Alphapharm, as part of Merck KgaA, is also dedicated to diabetes research. Currently, Alphapharm are investigating medications that will better manage diabetes complications, as well as prevent or delay diabetes developing. www.diabetesnsw.com.au /bgl_campaign_pages/alphapharm.asp   (237 words)

TPNA - Press Releases A federal judge of the U.S. District Court for the Southern District of New York ruled on February 21, 2006, that a patent covering the active ingredient of ACTOS® is valid and enforceable. Alphapharm and Mylan were the only defendants to challenge the ‘777 patent. Trial of the challenges by Alphapharm and Mylan to the validity and enforceability of the ‘777 patent took place from January 17, 2006 to January 30, 2006. www.tpna.com /prdetail.asp?articleid=116   (404 words)

About Seniors | Seniors Health Information & Resources Alphapharm has been manufacturing medicines in Australia since 1982 and is now the largest manufacturer of the broadest range of prescription medicines in Australia. Alphapharm generic medicines are as high in quality as the originator brand. Alphapharm medicines have the same active ingredient, in the same dose and work in the same way as the more expensive branded medicines. www.aboutseniors.com.au /index.php/articles/category/seniors_health_information_and_resources   (4693 words)

Diabetes Australia - NSW Alphapharm’s field force was responsible for hand-delivering most of the GP Information Packs to nearly all doctors’ practices around the country. Over a three-week period before the launch, Alphapharm’s field force delivered armfuls of GP Information Kits containing a covering letter, GP Advice Card, a wall poster, 1.1 million ‘rub ‘n’ reveal’ patient self test questionnaires and 540, 000 Just been diagnosed stick-it notes, to almost 9,000 practices around the country. Mr Harris said this was the second year that Alphapharm had supported the BGL campaign and their contribution helped ensure its success. www.diabetesnsw.com.au /pre_diabetes_campaign_pages/our_sponsers.asp   (304 words)

Press Release The Settlement Agreement with Alphapharm does not settle the pending patent litigation by Forest and Lundbeck against Ivax Pharmaceuticals, Inc. jointly with Cipla Ltd, ("IVAX") and does not affect the status of Ivax as an ongoing defendant in the pending litigation. Howard Solomon, Chairman and Chief Executive Officer of Forest, stated: "We are pleased to have concluded this settlement with Alphapharm. We continue to have confidence in the validity of our Lexapro patent and the terms of the settlement with Alphapharm are clearly consistent with that view of our patent's validity. www.frx.com /news/PressRelease.aspx?ID=764929   (413 words)

Pharmaceuticals Partnerships Program: Round Two Offers Alphapharm is a leading generic medicines manufacturer and is Australia's largest supplier of prescription medicines in volume terms to the Pharmaceutical Benefits Scheme, specialising in bringing generic medicines to the market and committed to RandD of innovative medicines with a portfolio of 550 products exported to more than 40 countries. Alphapharm is proposing RandD to develop stable, bioequivalent products to listed drugs on the Australian, US and other markets. Alphapharm is eligible for four years of funding of approximately $1.9 million, on the basis of forecast expenditures of $19.6 million. www.ausindustry.gov.au /content/content.cfm?ObjectID=CFFCCCD8-2270-4C8C-AF7E2DB8A2B5D07A&L2Parent=AEB901E5-7CB8-4143-A3BF33B2423F9DA6&L3Parent=C415AE0D-28C5-4D51-8FF2482EC1963838   (804 words)

Graduate Careers, Recruitment & Graduate Programs for Students at Grad Careers Australia | Graduate Careers Alphapharm is committed to the highest level of structured training and development and exceptional on the job experience. At Alphapharm, we take care of our people by providing unmatched benefits and opportunities for our staff. At Alphapharm you will be working for a company with an active involvement in our local and global community and generous humanitarian support. www.gradcareers.com.au /employer/profile/1913/Company_Profile   (296 words)

Publications & research - AGS publications - Commercial notes No. 12 Finemores’ defence was that Alphapharm was precluded from suing in negligence by clause 6 of the Conditions of Contract. However, the Court of Appeal addressed this issue, deciding that there was no contract between Alphapharm and Finemores – that is, RT had not been acting as Alphapharm’s agent when it entered into the agreement with Finemores for the delivery of the vaccine to Alphapharm’s customers. Its conditions were expressed to bind all who had an interest in the goods, and it required the customer to warrant that it had authority to act as their agent as well as on its own behalf. www.ags.gov.au /publications/agspubs/legalpubs/commercialnotes/ComNote12.htm   (3293 words)

Orange Book Blog: Federal Circuit Affirms Validity of Takeda's Actos Patent, Rejecting Alphapharm's Obviousness ... The decision is particularly important because the generic challenger, Alphapharm, had argued on appeal that the Supreme Court's recent decision in KSR v. Alphapharm argued that pioglitazone HCl would have been prima facie obvious over a prior art compound, named "compound b," that is structurally similar to pioglitazone. The district court found that there was no motivation in the prior art to select compound b as a lead compound in the first place, and that the prior art taught away from its use as a lead compound. www.orangebookblog.com /2007/06/federal-circuit.html   (549 words)

Forest Laboratories, Inc. :: Forest Laboratories and Lundbeck Enter Into Settlement Agreement With Alphapharm Related ... Forest and Lundbeck will agree to appoint Alphapharm as the exclusive distributor of generic versions of Lexapro(R), which may be launched under the scenarios outlined below. (a) In the event that Forest and Lundbeck are successful in their infringement action against IVAX regarding the '712 patent, the distribution arrangement with Alphapharm will only commence two weeks prior to the expiration of the '712 patent. Under either scenario Forest will receive from Alphapharm a portion of the profit from such generic sales in consideration of the license. sev.prnewswire.com /medical-pharmaceuticals/20051006/NYTH02606102005-1.html   (449 words)

Australian Made Campaign   (Site not responding. Last check: 2007-11-01) Alphapharm is Australia’s leading supplier of prescription pharmaceuticals. While we specialise in bringing patent-expired medicines to market, we also research and developinnovative medicines to prevent the development and spread of cancers, and to treat cardiovascular and metabolic diseases. Alphapharm pioneered generic medicines in Australia in 1982, setting up as a small pharmaceutical manufacturer in Queensland, with 12 staff and four products.We now have 740 highly skilled staff that research, develop, manufacture, distribute and market more than 550 different prescription and pharmacy-only medicines sold in 40 countries. www.australianmade.com.au /company/comp2377.asp   (108 words)

Welcome to Alphapharm Register and maintain Alphapharm products to the health authorities around the world. We are seeking outstanding sales professionals to take advantage of our fantastic career opportunities. Alphapharm welcomes your general expression of interest for vacancies that match your aspirations, qualifications and experience. careers.alphapharm.com.au /searchresults.asp   (82 words)

RealMoney.com: Forest Settles Lexapro Suit The Ivax dispute goes to trial Dec. 5, and this is the most significant danger for Forest. Thursday's settlement with Alphapharm is "a minor positive," adds Marc Goodman of Morgan Stanley, in a research note upholding his equal-weight rating on Forest. The deal means Alphapharm, which is owned by the German chemical and drug giant Merck KGaA, acknowledges the validity of the key Lexapro patent. www.thestreet.com /p/stocks/robertsteyer/10246149.html   (359 words)

Health Care Professional Information Center: Court Says No Private Right of Action On Hatch-Waxman Notice Requirements Alphapharm sent a so-called paragraph IV notice to 3M stating that its generic product did not infringe the 3M product, but 3M sued Alphapharm for patent infringement, triggering the automatic 30-month stay of FDA approval of the generic. Barr, the second ANDA filer, was subject both to the 30-month stay and to the 180-day generic exclusivity period held by Alphapharm, the first-to-file generic applicant. The 180-day period, which prevents later generic ANDA-filers from launching their products, begins to run either when the first ANDA filer begins to market its product or when a court decides the patent on the brand-name product is invalid or not infringed. healthcenter.bna.com /pic2/hc.nsf/8e9ea8728473b3be852569f9005d302a/23365706e99179a685256c87006eb00d?OpenDocument   (2315 words)

Try your search on: Qwika (all wikis)

About us   |   Why use us?   |   Reviews   |   Press   |   Contact us   Copyright © 2005-2007 www.factbites.com Usage implies agreement with terms.